Arcutis Biotherapeutics Inc Insider Trading
Every director, officer and 10% holder of Arcutis Biotherapeutics Inc has to report each trade in its stock within two business days of making it. This is those filings.
ARQT on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Masaru MatsudaSee Remarks2026-09-163.7K shat $25.00 | Sale10b5-1 plan | $91.9K |
| Howard G. WelgusDirector2026-09-154.7K shat $24.18 | Sale10b5-1 plan | $114.4K |
| Masaru MatsudaSee Remarks2026-09-0810K shat $25.03 | Sale10b5-1 plan | $250K |
| Terrie CurranDirector2026-08-2711.1K shat $25.03 | Sale | $279K |
| Terrie CurranDirector2026-08-2727.1K shat $25.03 | Sale | $677.1K |
| Terrie CurranDirector2026-08-201.1K shat $26.04 | Sale | $27.9K |
| Patrick BurnettSee Remarks2026-08-191.7K shat $27.00 | Sale | $45.8K |
| Howard G. WelgusDirector2026-08-174.7K shat $26.18 | Sale10b5-1 plan | $123.8K |
| Patrick BurnettSee Remarks2026-08-126.7K shat $26.08 | Sale | $174.8K |
| Patrick BurnettSee Remarks2026-08-118.3K shat $26.52 | Sale | $220.1K |
| Patrick BurnettSee Remarks2026-08-03955 shat $26.12 | Sale10b5-1 plan | $24.9K |
| Masaru MatsudaSee Remarks2026-08-031.2K shat $26.12 | Sale10b5-1 plan | $32.1K |
| Todd WatanabeSee Remarks2026-08-034.4K shat $26.12 | Sale10b5-1 plan | $114.3K |
| Howard G. WelgusDirector2026-07-154.7K shat $26.91 | Sale10b5-1 plan | $127.3K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on ARQT
Follow Arcutis Biotherapeutics Inc (ARQT) by email
New trades in Arcutis Biotherapeutics Inc (ARQT) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.